Randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects

Trial Profile

Randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs AP-30663 (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Acesion Pharma
  • Most Recent Events

    • 18 Feb 2018 Status changed from planning to recruiting.
    • 13 Feb 2018 New trial record
    • 08 Feb 2018 According to an Acesion Pharma media release, this trial will be onducted at the Centre for Human Drug Research (CHDR) in the Netherlands.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top